Blood Advances is a semimonthly medical journal published by the American Society of Hematology. It is the first journal to join the Blood family in 70 years and is a peer-reviewed, online only, open access journal. Under the direction of founding editor-in-chief Robert Negrin, MD, Stanford University Medical Center, Stanford, CA, the inaugural issue debuted on November 29, 2016.Blood Advances provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. The journal covers all aspects of hematology, including disorders of leukocytes, both benign and malignant, erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. All articles undergo a rigorous peer-review and are selected on the basis of the originality of the findings, the superior quality of the work described, and the clarity of presentation.
《血液进展》（Blood Advances）是美国血液学会出版的半月刊医学杂志。这是70年来第一个加入血液家族的期刊，是一个同行评议的，仅在线的，开放获取的期刊。在创始主编Robert Negrin（医学博士，斯坦福大学大学医学中心，斯坦福，加利福尼亚州）的指导下，创刊号于2016年11月29日首发。《血液进展》为发表描述血液学基础实验室、转化和临床研究的原创文章提供了一个国际论坛。该杂志涵盖血液学的所有方面，包括白细胞疾病，良性和恶性，红细胞，血小板，止血机制，血管生物学，免疫学和血液肿瘤学。所有文章都经过严格的同行评审，并根据研究结果的原创性、所描述工作的上级质量和陈述的清晰度进行选择。
American Society of Hematology 2019 guidelines for immune thrombocytopenia.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000966
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000360
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000644
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018029496
Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000820
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000692
Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018025718
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000593
Emicizumab use in major orthopedic surgery.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000228
Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000476
A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000300
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000717
Metabolomic and molecular insights into sickle cell disease and innovative therapies.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018030619
Baboon envelope LVs efficiently transduced human adult, fetal, and progenitor T cells and corrected SCID-X1 T-cell deficiency.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018027508
Identification of a tumor-specific allo-HLA-restricted γδTCR.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019032409
Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018024216
Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000380
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019032276
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000722
Butyrogenic bacteria after acute graft-versus-host disease (GVHD) are associated with the development of steroid-refractory GVHD.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000362
Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000516
Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000068
Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000934
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000640
Genome-wide promoter methylation of hairy cell leukemia.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018024059
IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018026591
Identification of recurrent noncoding mutations in B-cell lymphoma using capture Hi-C.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018026419
Platelets inhibit apoptotic lung epithelial cell death and protect mice against infection-induced lung injury.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018026286
Impact of acquired del(17p) in multiple myeloma.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018028530
Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance.
来源期刊：Blood advancesDOI：10.1182/BLOODADVANCES.2019000400
Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000378
Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019031450
Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018026054
Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000655
Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.
来源期刊：Blood advancesDOI：10.1182/BLOODADVANCES.2017007914
Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000167
Generation and function of progenitor T cells from StemRegenin-1-expanded CD34+ human hematopoietic progenitor cells.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018026575
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019001068
High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000450
TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000374
Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019030858
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000883
Large-scale in vitro production of red blood cells from human peripheral blood mononuclear cells.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000689
Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018028886
Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018019851
Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018026203
Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018026047
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000051
Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2019000465
Childhood use of antimicrobials and risk of Hodgkin lymphoma: a Danish register-based cohort study.
来源期刊：Blood advancesDOI：10.1182/bloodadvances.2018029355
